Edit |   |
---|---|
Antigenic Specificity | c-myc, Human |
Clone | REAL810 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | fluorescein (FITC) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | c-myc Antibody, anti-human, FITC, REAdye_lease™. Clone REAL810 is an antibody fragment derived from the full c-myc antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL810 recognizes the multifunctional, nuclear phosphoprotein c-myc, a transcriptional regulator protein, also known as MYC, that is involved in cell cycle progression, apoptosis and cellular transformation. Deregulation including overexpression and mutations of c-myc contributes to the genesis of most human tumors. Expression of c-myc is found in many cancer tissues, e.g. hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
Immunogen | n/a |
Other Names | bHLHe39, c-Myc, MYCC |
Gene, Accession # | n/a |
Catalog # | 130-126-065 |
Price | $390 |
Order / More Info | c-myc, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Amati, B. et al. (1994) Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr. Opin. Genet. Dev.: 102-108. | Adhikary, S. and Eilers, M. et al. (2005) Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6 (8): 635-645. |